937014-80-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Boc-1-[(3-Bromobenzene)sulfonyl]piperazine is used as an intermediate in the synthesis of various drugs for its role in the production of antidepressants and antihistamines. Its presence in the synthesis process contributes to the development of medications that address mental health and allergy-related conditions.
Used in Agrochemical Industry:
As an intermediate in the synthesis of agrochemicals, 4-Boc-1-[(3-Bromobenzene)sulfonyl]piperazine plays a crucial role in the development of products designed to protect crops and enhance agricultural productivity.
Used in Organic Synthesis:
4-Boc-1-[(3-Bromobenzene)sulfonyl]piperazine is used as an important reagent in organic synthesis for its ability to facilitate the formation of carbon-carbon and carbon-nitrogen bonds, which are essential in creating a wide range of chemical compounds with various applications.

Upstream product

• 591-19-5 m-Bromoaniline 
• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1377550-30-5 5-(3-(4-(3-(4-isopropylphenyl)pyrazin-2-yl)piperazin-1-ylsulfonyl)phenyl)pyrimidin-2-amine 
• 1377551-39-7 C₁₉H₂₅N₅O₄S 
• 1377551-42-2 C₁₈H₁₈ClN₇O₂S 
• 1033743-83-7 C₂₁H₃₃BN₂O₆S 

Relevant academic research and scientific papers

Discovery of Novel Chromone Derivatives Containing a Sulfonamide Moiety as Anti-ToCV Agents through the Tomato Chlorosis Virus Coat Protein-Oriented Screening Method

A number of novel chromone derivatives containing sulfonamide moieties were designed and synthesized, and the activity of compounds against tomato chlorosis virus (ToCV) was assessed using the ToCVCP-oriented screening method. Comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) models were established based on the dissociation constant (Kd) values of the target compounds, and compound 35 was designed and synthesized with the aid of CoMFA and CoMSIA models. The study of affinity interaction indicated that compound 35 exhibited excellent affinity with ToCVCP with a Kd value of 0.11 μM, which was better than that of the positive control agents xiangcaoliusuobingmi (0.44 μM) and ningnanmycin (0.79 μM). In addition, the in vivo inhibitory effect of compound 35 on the ToCVCP gene was evaluated by the quantitative real-time polymerase chain reaction. ToCVCP gene expression levels of the compound 35 treatment group were reduced by 67.2%, which was better than that of the positive control agent ningnanmycin (59.5%). Therefore, compound 35 can be used as a potential anti-ToCV drug in the future.

BENZAZEPINE SULFONAMIDE COMPOUNDS

This invention relates to novel benzazepine sulfonamide compounds of the formula (I), wherein R4 or R5 is -SO2-NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are TLR agonists and may therefore be useful as medicaments for the treatment of diseases such as cancer, autoimmune diseases, inflammation, sepsis, allergy, asthma, graft rejection, graft-versus-host disease, immunodeficiencies, and infectious diseases.

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors

The phosphoinositide 3-kinases (PI3Ks) have been linked to an extraordinarily diversified group of cellular functions making these enzymes compelling targets for the treatment of disease. A large body of evidence has linked PI3Kγ to the modulation of autoimmune and inflammatory processes making it an intriguing target for drug discovery. Our high-throughput screening (HTS) campaign revealed two hits that were nominated for further optimization studies. The in vitro activity of the first HTS hit, designated as the sulfonylpiperazine scaffold, was optimized utilizing structure-based design. However, nonoptimal pharmacokinetic properties precluded this series from further studies. An overlay of the X-ray structures of the sulfonylpiperazine scaffold and the second HTS hit within their complexes with PI3Kγ revealed a high degree of overlap. This feature was utilized to design a series of hybrid analogues including advanced leads such as 31 with desirable potency, selectivity, and oral bioavailability.

New phenylpyridylpiperazine compounds

A compound selected from those of formula (I): [image] wherein: X represents a C(O) or SO2 group, R1 represents an aryl group or a group NR3R4 wherein R3 and R4 are as defined in the description, R2 represents an alkyl, (C3-C8)cycloalkyl or (C3-C8)cycloalkyl-(C1-C6)alkyl group, its isomers, and addition salts thereof, and medicinal products containing the same which are useful in treating conditions treatable by antagonists of type H3 central histamine receptors.